Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvir

Mostrar otras versiones (1)

The SARS-CoV-2 main protease (M(pro)) is the drug target of Pfizer’s oral drug Paxlovid. The emergence of SARS-CoV-2 variants with mutations in M(pro) raised the alarm of potential drug resistance. In this study, we identified 100 naturally occurring M(pro) mutations located at the nirmatrelvir bind...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Yanmei, Lewandowski, Eric M., Tan, Haozhou, Zhang, Xiaoming, Morgan, Ryan T., Zhang, Xiujun, Jacobs, Lian M. C., Butler, Shane G., Gongora, Maura V., Choy, John, Deng, Xufang, Chen, Yu, Wang, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479041/
https://www.ncbi.nlm.nih.gov/pubmed/36119652
http://dx.doi.org/10.1101/2022.06.28.497978

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479041/
https://www.ncbi.nlm.nih.gov/pubmed/36119652
http://dx.doi.org/10.1101/2022.06.28.497978

Ejemplares similares